Samsung Biologics Highlights Faster Drug Manufacturing Timelines at BPI Boston
4 Articles
4 Articles
Samsung Biologics announced on the 28th that it unveiled its manufacturing strategy at the ‘2026 Bioprocess International’ (BPI) event recently held in Boston, USA. This is an event where corporate officials and experts gather to share the latest trends related to the development and production of biopharmaceuticals. Samsung Biologics has attended Bioprocess International for nine consecutive years since 2018. At an exclusive booth this year, th…
(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Biologics [207940] at the global bio-industry conference '2026 Bioprocess International (BPI)' ...
Samsung Biologics has achieved a significant milestone by drastically shortening the biopharmaceutical development period from the previous 13 months to 9.5 months. This result was achieved by designing customized processes for each molecule based on Integrated Manufacturing and Quality Control (CMC), thereby increasing speed while maintaining quality. Samsung Biologics introduced this process innovation strategy at the prestigious bio-industry…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
